ObesityWeek 2025 – De-escalation strategy cuts GLP-1 dosing frequency in half without loss of metabolic benefits
A new approach proposes biweekly GLP-1 maintenance, preserving weight loss and metabolic improvements in patients previously stabilized on weekly therapy.
TribeMD
3 min read
November 5, 2025
Carregando conteúdo…
Obesity Week 2025
Cardiometabolics
Highlights
SnackableHealth® |Non-cardiac effects in HELIOS-B trial: gastrointestinal symptoms and quality-of-life signals discussed by Drs. Mike Gibson and Tony Urey
ASCO GU® 2026
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer
SnackableHealth® |Non-cardiac effects in HELIOS-B trial: gastrointestinal symptoms and quality-of-life signals discussed by Drs. Mike Gibson and Tony Urey
ASCO GU® 2026
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer